BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheon IS, Shim BS, Park SM, Choi Y, Jang JE, Jung DI, Kim JO, Chang J, Yun CH, Song MK. Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf). PLoS One 2014;9:e94269. [PMID: 24736750 DOI: 10.1371/journal.pone.0094269] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Khan IU, Ahmad F, Zhang S, Lu P, Wang J, Xie J, Zhu N. Respiratory syncytial virus F and G protein core fragments fused to HBsAg-binding protein (SBP) induce a Th1-dominant immune response without vaccine-enhanced disease. International Immunology 2019;31:199-209. [DOI: 10.1093/intimm/dxy078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Walpita P, Johns LM, Tandon R, Moore ML. Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract. PLoS One 2015;10:e0130755. [PMID: 26172453 DOI: 10.1371/journal.pone.0130755] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
3 Rivera CA, Gómez RS, Díaz RA, Céspedes PF, Espinoza JA, González PA, Riedel CA, Bueno SM, Kalergis AM. Novel therapies and vaccines against the human respiratory syncytial virus. Expert Opinion on Investigational Drugs 2015;24:1613-30. [DOI: 10.1517/13543784.2015.1099626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
4 Vaughan K, Ponomarenko J, Peters B, Sette A. Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present. PLoS One 2015;10:e0127108. [PMID: 26001197 DOI: 10.1371/journal.pone.0127108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Jorquera PA, Anderson L, Tripp RA. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Rev Vaccines 2016;15:173-87. [PMID: 26641318 DOI: 10.1586/14760584.2016.1115353] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
6 Jo YM, Kim J, Chang J. Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus. Clin Exp Vaccine Res 2019;8:43-53. [PMID: 30775350 DOI: 10.7774/cevr.2019.8.1.43] [Reference Citation Analysis]
7 Lee JY, Chang J. Universal vaccine against respiratory syncytial virus A and B subtypes. PLoS One 2017;12:e0175384. [PMID: 28384263 DOI: 10.1371/journal.pone.0175384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]